FIG 2.

Effect of compound treatment on binding of EBOV to the cell surface. (A) HeLa cells were pretreated with 50 μM of the indicated compound for 1 h and were then incubated with wild-type EBOV for 2.5 h. The cells were then fixed and stained without permeabilization using an EBOV GP-specific antibody followed by an Alexa Fluor 546-labeled secondary antibody (red). Cell bodies were stained using CellMask blue. 3D modeling of deconvolved image z-stacks was done using Imaris software. (B) The number of virus particles present on the cell surface was counted. (C) A second analysis of the number of cells that had no virus bound was also performed. Data are the averages ± SDs for at least 100 cells. All assays were performed 3 times with similar outcomes each time. *, P < 0.05; **, P < 0.01; ***, P < 0.001.